Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
BIOCON TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-23 |
TEVA PHARMA Dec-13 |
BIOCON / TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 388 | 3,480 | - | |
Low | Rs | 192 | 3,023 | - | |
Sales per share (Unadj.) | Rs | 93.1 | 1,997.4 | - | |
Earnings per share (Unadj.) | Rs | 5.4 | 124.8 | - | |
Cash flow per share (Unadj.) | Rs | 14.6 | 286.2 | - | |
Dividends per share (Unadj.) | Rs | 1.50 | 109.23 | - | |
Avg Dividend yield | % | 0.5 | 3.4 | 15.4% | |
Book value per share (Unadj.) | Rs | 146.5 | 2,218.7 | - | |
Shares outstanding (eoy) | m | 1,200.60 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.1 | 1.6 | 191.2% | |
Avg P/E ratio | x | 54.1 | 26.1 | 207.6% | |
P/CF ratio (eoy) | x | 19.8 | 11.4 | 174.3% | |
Price / Book Value ratio | x | 2.0 | 1.5 | 134.9% | |
Dividend payout | % | 28.0 | 87.5 | 32.0% | |
Avg Mkt Cap | Rs m | 347,814 | 2,757,543 | 12.6% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 21,810 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,685.6 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,354.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 111,742 | 1,693,781 | 6.6% | |
Other income | Rs m | 7,681 | 0 | - | |
Total revenues | Rs m | 119,423 | 1,693,781 | 7.1% | |
Gross profit | Rs m | 16,611 | 463,843 | 3.6% | |
Depreciation | Rs m | 11,131 | 136,910 | 8.1% | |
Interest | Rs m | 4,190 | 33,269 | 12.6% | |
Profit before tax | Rs m | 8,971 | 293,664 | 3.1% | |
Minority Interest | Rs m | 0 | 1,334 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,775 | -0.0% | |
Tax | Rs m | 2,541 | -3,585 | -70.9% | |
Profit after tax | Rs m | 6,430 | 105,809 | 6.1% | |
Gross profit margin | % | 14.9 | 27.4 | 54.3% | |
Effective tax rate | % | 28.3 | -1.2 | -2,320.0% | |
Net profit margin | % | 5.8 | 6.2 | 92.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 123,340 | 1,143,974 | 10.8% | |
Current liabilities | Rs m | 85,107 | 997,642 | 8.5% | |
Net working cap to sales | % | 34.2 | 8.6 | 396.0% | |
Current ratio | x | 1.4 | 1.1 | 126.4% | |
Inventory Days | Days | 129 | 91 | 142.1% | |
Debtors Days | Days | 117 | 96 | 121.7% | |
Net fixed assets | Rs m | 394,078 | 553,226 | 71.2% | |
Share capital | Rs m | 6,003 | 4,169 | 144.0% | |
Net worth | Rs m | 175,929 | 1,881,470 | 9.4% | |
Long term debt | Rs m | 152,905 | 866,068 | 17.7% | |
Total assets | Rs m | 517,418 | 3,870,833 | 13.4% | |
Interest coverage | x | 3.1 | 9.8 | 32.0% | |
Debt to equity ratio | x | 0.9 | 0.5 | 188.8% | |
Sales to assets ratio | x | 0.2 | 0.4 | 49.4% | |
Return on assets | % | 2.1 | 3.6 | 57.1% | |
Return on equity | % | 3.7 | 5.6 | 65.0% | |
Return on capital | % | 4.0 | 4.9 | 81.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 18,525 | 269,901 | 6.9% | |
From Investments | Rs m | -142,818 | -95,637 | 149.3% | |
From Financial Activity | Rs m | 130,487 | -323,765 | -40.3% | |
Net Cashflow | Rs m | 6,411 | -149,500 | -4.3% |
Compare BIOCON With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare BIOCON With: MERCURY LAB. GRANULES INDIA CONCORD BIOTECH KILITCH DRUGS PIRAMAL PHARMA
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.